Hematologic Malignancies
Conference Coverage
Variant not linked to CLL in Southeast Europe
DUBROVNIK, CROATIA – The PTPN22 R620W polymorphism was not associated with CLL in patients from Southeast Europe.
Conference Coverage
Researchers consider R/R ALL drugs in the first-line setting
CHICAGO –
Conference Coverage
Will quad therapy become the new standard in myeloma?
NEW YORK – Phase 2 studies have shown high response rates for four-drug combinations targeting multiple myeloma.
Conference Coverage
Real-world clues for optimal sequencing of CLL novel agents
NEW YORK – Dr. John Allan of Cornell University said
Conference Coverage
STORM trial shows response in penta-refractory myeloma
Selinexor and low-dose dexamethasone produced a “clinically meaningful benefit” in the phase 2 trial.
Conference Coverage
Implementation of a Hematology VA-ECHO Program
Conference Coverage
Occurrence of Skeletal-Related Events in Multiple Myeloma and Prostate Cancer Patients Receiving Standard Versus Extended-Interval Zoledronic Acid
News
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients
Adverse events were largely seen during the first year of treatment and decreased over time.
News
FDA fast-tracks CX-01 for newly diagnosed AML
News
Fracture risk linked to mortality in women with myeloma
Researchers identified osteoporosis as an important prognostic factor in postmenopausal women.